Clinical trials: Endocrine System Disorder
Diabetes Mellitus, Type 2
Thiazolidinedione Intervention With Vitamin D Evaluation
This study will answer two separate questions. The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard…
- Trial name
- TIDE (NCT00879970)
- Testing
- pioglitazone, rosiglitazone, Vitamin D
- Where
- 331 sites in United States, Argentina and 23 more
- Volunteers
- 1,332 people
- Sponsor
- GlaxoSmithKline
PROC, Platinum Resistant Ovarian Cancer
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.
- Conditions
- PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT07470853
- Testing
- HWK-016, MUCIN-16-targeted ADC, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 265 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Safety, Tolerability
A Study of GensSci098 in Subjects With Graves' Disease
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
- Conditions
- Safety, Tolerability, GenSci098, Graves Disease
- Trial name
- NCT07286656
- Testing
- GenSci098
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Early T2DM With Obesity
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise.
- Trial name
- NCT07743983
- Testing
- BGM0504, semaglutide
- Where
- China
- Volunteers
- 372 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Ovarian Cancer
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
The primary objective of this extension protocol is to evaluate the early safety of a new schedule of NGR-hTNF given weekly, instead of every 3 or 4 weeks, in a cohort of 12 patients randomized to the experimental arm A, as…
- Trial name
- NCT03804866
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 4 sites in Italy
- Volunteers
- 14 people
- Sponsor
- AGC Biologics S.p.A.
Pancreas Cancer, Pancreatic Cancer
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage IV, Pancreatic Cancer Stage III
- Trial name
- NCT04137822
- Testing
- IMM-101
- Where
- 2 sites in France, United Kingdom
- Sponsor
- Impatients N.V. trading as myTomorrows
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
Diabetes Mellitus, Type 2
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
The objective of the study is to investigate the efficacy and safety of linagliptin 2.5 mg twice daily compared to 5 mg once daily compared to placebo given orally for 12 weeks as add-on therapy to metformin in patients with type…
- Trial name
- NCT01012037
- Testing
- linagliptin low dose, linagliptin medium dose
- Where
- 84 sites in Belgium, Canada and 7 more
- Volunteers
- 491 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2, GI Side Effect
Glucophage XR® Observational Study
This is a non-interventional, prospective study where no visits or additional interventions to the daily practice of the physician will be performed.
- Trial name
- NCT01336673
- Where
- Thailand
- Volunteers
- 518 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus, Type II
GOLO Open-Label Pilot 1
The objective of this open-label pilot study is to evaluate the effect of the commercially available GOLO for Life (GFL) weight management program on body weight in a type 2 diabetic patient population after approximately 3…
- Trial name
- NCT03478202
- Testing
- GOLO RELEASE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Golo
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Nephropathy, Diabetic
- Trial name
- NCT04534439
- Testing
- APX-115
- Where
- 16 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 140 people
- Sponsor
- Aptabio Therapeutics, Inc.
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2
Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
Study Primary Objectives: To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral…
- Trial name
- NCT01336751
- Testing
- Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Sanofi
Diabetic Foot
Efficacy of Human Placental Graft in Diabetic Foot Ulcers
To determine the efficacy of full-thickness placental allograft in chronic wound healing
- Trial name
- NCT03708029
- Testing
- Revita Allograft
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- StimLabs
Pre Diabetes, Prediabetic State
Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects
This clinical study aims to prove that the efficacy of non digestible carbohydrates supplementation (daily dose of 20 grams consumed twice a day for 12 weeks) on the regulation of glucose homeostasis is superior than placebo in…
- Conditions
- Pre Diabetes, Prediabetic State, Dysglycemia, PreDiabetes
- Trial name
- FOS_GLUCOSE (NCT04767672)
- Testing
- Non digestible carbohydrates
- Where
- 3 sites in France
- Volunteers
- 66 people
- Sponsor
- Tereos
Diabetes, Healthy
Safety and Tolerability of Liraglutide in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after five ascending single doses of NNC 90-1170 (liraglutide).
- Trial name
- NCT01507272
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.